Suchergebnisse - "Xuhong, Juncheng"

PubPharm (7)

1

Pyrotinib-based therapeutic approaches for HER2-positive breast cancer : the time is now

enthalten in: Breast cancer research : BCR | 2023

von Qi, X. | Shi, Q. | Xuhong, J. | +2

2

Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now

enthalten in: Breast cancer research | 2023

von Qi, X. | Shi, Q. | Xuhong, J. | +2

3

Predictive and prognostic value of PIK3CA mutations in HER2-positive breast cancer treated with tyrosine kinase inhibitors : A systematic review and meta-analysis

enthalten in: Biochimica et biophysica acta. Reviews on cancer | 2023

von Shi, Q. | Xuhong, J. | Tian, H. | +4

4

PIK3CA mutations are associated with pathologic complete response rate to neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer

enthalten in: British journal of cancer | 2023

von Shi, Q. | Xuhong, J. | Luo, T. | +14

5

Development and validation of a prognostic nomogram for early HER2-positive and lymph node-negative breast cancer

enthalten in: Gland surgery | 2021

von Shi, Q. | Wang, J. | Ai, X. | +5

6

Neoadjuvant Pyrotinib plus Trastuzumab and Chemotherapy for Stage I-III HER2-Positive Breast Cancer : A Phase II Clinical Trial

enthalten in: The oncologist | 2020

von Xuhong, J. | Qi, X. | Tang, P. | +12

7

Neoadjuvant Pyrotinib plus Trastuzumab and Chemotherapy for Stage I– III HER2‐Positive Breast Cancer : A Phase II Clinical Trial

enthalten in: The oncologist | 2020

von Xuhong, J. | Qi, X. | Tang, P. | +12

1
[1]